Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth M Steinberg

Showing results (411-420 of 481) with videos related to

Pageof 49
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan, James C Yang, Richard M Sherry, et al.
The Oncologist|February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
JAMA Oncology|February 20, 2025
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical TrialCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Oncoimmunology|September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancerLauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Blood Advances|January 4, 2018
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaSham Mailankody, Dickran Kazandjian, Neha Korde, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2025
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancerCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Pageof 49

Showing results (411-420 of 481) with videos related to

Sort By:
Pageof 49
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan, James C Yang, Richard M Sherry, et al.
The Oncologist|February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
JAMA Oncology|February 20, 2025
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical TrialCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Oncoimmunology|September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancerLauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Blood Advances|January 4, 2018
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaSham Mailankody, Dickran Kazandjian, Neha Korde, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2025
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancerCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Pageof 49